The documented product record for this firm centers on one device family and one open enforcement action. FDA enforcement report Z-0089-2027 lists Nihon Kohden America LLC of Irvine, California as the recalling firm for the CNS-6200 Series Central Nurse Station, model CN-6201, across software versions 01-03, 01-04, 01-05, 01-06, 02-10, 02-11 and 02-40, with a product quantity of 808 units. The stated reason is a cybersecurity issue associated with a NULL pointer dereference vulnerability that, if exploited, would potentially cause disruption of centralized monitoring of multiple beds and the visualization of alarms. The action is classified Class II, described as voluntary and firm initiated, with a recall initiation date of September 8, 2026 and a center classification date of October 6, 2026. [1][2][9]
The device and its stated function
The CNS-6200 Series Central Nurse Station is described in the FDA record as intended for use by medical professionals to provide cardiac and vital signs monitoring for multiple patients within a medical facility. The station displays and records physiological data from up to forty telemetry receiver/transmitters and generates an alarm when a measured parameter falls outside a pre-set limit or when life-threatening arrhythmia is detected. The same description states that arrhythmia detection and alarm determination are functions of the telemetry receivers/transmitters or individual bedside monitors rather than of the central station itself. [1]
A separate FDA premarket record, 510(k) K102376, identifies the NIHON KOHDEN CNS-6200 SERIES CENTRAL NURSE STATION, MODEL CNS-6201, under the device classification Monitor, Physiological, Patient (With Arrhythmia Detection Or Alarms), product code MHX. That filing names Nihon Kohden Corp. as the applicant, with a Foothill, California address listed in the filing. The premarket applicant and the recalling firm are distinct legal entities in the records, and the filing address is a filing detail rather than a verified headquarters. [8]
Scope and status of the enforcement action
The recall covers seven software versions of model CN-6201 and a stated quantity of 808 units. The initial firm notification was by letter, and the record lists distribution across a long set of U.S. states plus QA. The FDA recall database entry for the same event shows a firm-initiated date of September 8, 2026, a posting date of October 6, 2026, and a status of open, with the page last updated November 13, 2026. [1][2]
An independent aggregator, recallrecordindex.com, reports ten recall events for Nihon Kohden America from 2012 to 2026, none Class I, six ongoing, with the most recent initiated September 8, 2026, and five FDA inspections on file, the last ending October 4, 2024, with three Voluntary Action Indicated and two No Action Indicated outcomes. Those counts are the aggregator's own tabulation of FDA data as of November 4, 2026 and are not a measure of safety performance. A second aggregator, RegWarden, lists the recalling firm for the same event as Nihon Kohden Corp. while classifying it as a Nihon Kohden America LLC recall, and notes that openFDA recall records do not name a specific facility. [7][9]
Cybersecurity advisory context
CISA published ICS Medical Advisory ICSMA-25-296-01 on October 23, 2025 for the NIHON KOHDEN Central Monitor CNS-6201, listing affected versions 01-03, 01-04 and 01-05 among others. The advisory recommends defensive measures to minimize risk of exploitation and states that no known public exploitation specifically targeting the vulnerability had been reported to CISA at the time of publication. The advisory predates the September 2026 recall initiation and addresses the same product line. [5]
What the records do not establish
The available documents do not identify a verified parent company, corporate headquarters, website, customer list or commercial availability for Nihon Kohden America LLC beyond the Irvine, California address given as the recalling firm's address in the enforcement report. No clinical outcome data, certification or independent testing result appears in these records. The 510(k) record shows a related premarket clearance under a different applicant name, and the aggregator counts describe filing history rather than product performance. [1][7][8]

